Cytokines in primary headache disorders: a systematic review and meta-analysis.
Cytokine
Immunology
Migraine disorders
Neurogenic inflammation
Tension-type headache
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
04 Apr 2023
04 Apr 2023
Historique:
received:
13
02
2023
accepted:
28
03
2023
medline:
6
4
2023
entrez:
4
4
2023
pubmed:
5
4
2023
Statut:
epublish
Résumé
The role of inflammation and cytokines in the pathophysiology of primary headache disorders is uncertain. We performed a systematic review and meta-analysis to synthesise the results of studies comparing peripheral blood cytokine levels between patients with migraine, tension-type headache, cluster headache, or new daily persistent headache (NDPH), and healthy controls; and in migraine between the ictal and interictal stages. We searched PubMed/Medline and Embase from inception until July 2022. We included original research studies which measured unstimulated levels of any cytokines in peripheral blood using enzyme-linked immunosorbent assay or similar assay. We assessed risk of bias using the Newcastle-Ottawa Quality Assessment Scale. We used random effects meta-analysis with inverse variance weighted average to calculate standardised mean difference (SMD), 95% confidence intervals, and heterogeneity for each comparison. This study is registered with PROSPERO (registration number CRD42023393363). No funding was received for this study. Thirty-eight studies, including 1335 patients with migraine (32 studies), 302 with tension-type headache (nine studies), 42 with cluster headache (two studies), and 1225 healthy controls met inclusion criteria. Meta-analysis showed significantly higher interleukin (IL)-6 (SMD 1.07, 95% CI 0.40-1.73, p = 0.002), tumour necrosis factor (TNF)-α (SMD 0.61, 95% CI 0.14-1.09, p = 0.01), and IL-8 (SMD 1.56, 95% CI 0.03-3.09, p = 0.04), in patients with migraine compared to healthy controls, and significantly higher interleukin-1β (IL-1β) (SMD 0.34, 95% CI 0.06-0.62, p = 0.02) during the ictal phase of migraine compared to the interictal phase. Transforming growth factor (TGF)-β (SMD 0.52, 95% CI 0.18-0.86, p = 0.003) and TNF-α (SMD 0.64, 95% CI 0.33-0.96, p = 0.0001) were both higher in patients with tension-type headache than controls. The higher levels of the proinflammatory cytokines IL-6, IL-8 and TNF-α in migraine compared to controls, and IL-1β during the ictal stage, suggest a role for inflammation in the pathophysiology of migraine, however prospective studies are required to confirm causality and investigate the mechanisms for the increase in cytokine levels identified. Cytokines may also have a role in tension-type headache. Due a lack of data, no conclusions can be made regarding cluster headache or NDPH.
Sections du résumé
BACKGROUND
BACKGROUND
The role of inflammation and cytokines in the pathophysiology of primary headache disorders is uncertain. We performed a systematic review and meta-analysis to synthesise the results of studies comparing peripheral blood cytokine levels between patients with migraine, tension-type headache, cluster headache, or new daily persistent headache (NDPH), and healthy controls; and in migraine between the ictal and interictal stages.
METHODS
METHODS
We searched PubMed/Medline and Embase from inception until July 2022. We included original research studies which measured unstimulated levels of any cytokines in peripheral blood using enzyme-linked immunosorbent assay or similar assay. We assessed risk of bias using the Newcastle-Ottawa Quality Assessment Scale. We used random effects meta-analysis with inverse variance weighted average to calculate standardised mean difference (SMD), 95% confidence intervals, and heterogeneity for each comparison. This study is registered with PROSPERO (registration number CRD42023393363). No funding was received for this study.
RESULTS
RESULTS
Thirty-eight studies, including 1335 patients with migraine (32 studies), 302 with tension-type headache (nine studies), 42 with cluster headache (two studies), and 1225 healthy controls met inclusion criteria. Meta-analysis showed significantly higher interleukin (IL)-6 (SMD 1.07, 95% CI 0.40-1.73, p = 0.002), tumour necrosis factor (TNF)-α (SMD 0.61, 95% CI 0.14-1.09, p = 0.01), and IL-8 (SMD 1.56, 95% CI 0.03-3.09, p = 0.04), in patients with migraine compared to healthy controls, and significantly higher interleukin-1β (IL-1β) (SMD 0.34, 95% CI 0.06-0.62, p = 0.02) during the ictal phase of migraine compared to the interictal phase. Transforming growth factor (TGF)-β (SMD 0.52, 95% CI 0.18-0.86, p = 0.003) and TNF-α (SMD 0.64, 95% CI 0.33-0.96, p = 0.0001) were both higher in patients with tension-type headache than controls.
CONCLUSIONS
CONCLUSIONS
The higher levels of the proinflammatory cytokines IL-6, IL-8 and TNF-α in migraine compared to controls, and IL-1β during the ictal stage, suggest a role for inflammation in the pathophysiology of migraine, however prospective studies are required to confirm causality and investigate the mechanisms for the increase in cytokine levels identified. Cytokines may also have a role in tension-type headache. Due a lack of data, no conclusions can be made regarding cluster headache or NDPH.
Identifiants
pubmed: 37016284
doi: 10.1186/s10194-023-01572-7
pii: 10.1186/s10194-023-01572-7
pmc: PMC10071234
doi:
Substances chimiques
Cytokines
0
Tumor Necrosis Factor-alpha
0
Interleukin-8
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Informations de copyright
© 2023. The Author(s).
Références
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Headache. 1993 Nov-Dec;33(10):524-7
pubmed: 8294190
Headache. 1991 May;31(5):310-3
pubmed: 1860789
Brain Res Bull. 2015 Jul;116:98-105
pubmed: 26151770
Nat Rev Neurol. 2021 May;17(5):308-324
pubmed: 33782592
Neurology. 2019 Apr 23;92(17):e2038-e2050
pubmed: 30918090
Clin J Pain. 2015 Nov;31(11):959-67
pubmed: 25551477
Neurol Sci. 2018 Oct;39(10):1741-1749
pubmed: 30009333
BMJ Open. 2019 Apr 8;9(4):e026581
pubmed: 30962236
Headache. 2004 Nov-Dec;44(10):961-8
pubmed: 15546258
Cephalalgia. 2000 Mar;20(2):136
pubmed: 10961772
Neuroscience. 2013 Aug 29;246:199-229
pubmed: 23644052
Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):930-6
pubmed: 27010153
Cephalalgia. 2009 Mar;29(3):365-72
pubmed: 19175774
Headache. 2018 Jan;58(1):78-87
pubmed: 29131327
Biomedicines. 2021 Dec 30;10(1):
pubmed: 35052756
Int J Mol Sci. 2017 Feb 13;18(2):
pubmed: 28208835
Arq Neuropsiquiatr. 2021 Sep;79(9):789-794
pubmed: 34669816
Cephalalgia. 1993 Oct;13(5):343-5; discussion 307-8
pubmed: 7694804
Nat Rev Neurol. 2019 Aug;15(8):483-490
pubmed: 31263254
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12544-9
pubmed: 9770522
Curr Pain Headache Rep. 2021 Nov 11;25(11):73
pubmed: 34766205
Front Immunol. 2019 Jun 04;10:1229
pubmed: 31214186
Cephalalgia. 2001 Jun;21(5):549-57
pubmed: 11472381
J Clin Oncol. 1987 Dec;5(12):1942-51
pubmed: 3681377
Brain Stimul. 2019 May - Jun;12(3):643-651
pubmed: 30745260
Neurochem Int. 2002 Apr;40(4):301-6
pubmed: 11792459
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
PLoS One. 2011 Mar 04;6(3):e17360
pubmed: 21394197
J Clin Neurosci. 2022 Apr;98:213-218
pubmed: 35202991
Rheumatology (Oxford). 2021 Jun 18;60(6):2602-2614
pubmed: 33576773
J Neuroimmunol. 2006 Feb;171(1-2):184-8
pubmed: 16325275
Headache. 2007 Jul-Aug;47(7):1050-5
pubmed: 17635596
Iran J Allergy Asthma Immunol. 2020 May 17;19(S1):83-90
pubmed: 32534515
J Headache Pain. 2021 Jun 10;22(1):55
pubmed: 34112082
Pain Pract. 2009 Sep-Oct;9(5):375-9
pubmed: 19622115
Ann Indian Acad Neurol. 2019 Jul-Sep;22(3):277-281
pubmed: 31359937
Cephalalgia. 2022 Dec;42(14):1565-1588
pubmed: 35962530
J Mol Med (Berl). 1997 Jun;75(6):448-53
pubmed: 9231885
Pediatr Neurol. 2009 Jul;41(1):17-21
pubmed: 19520268
Headache. 1998 Jun;38(6):465-7
pubmed: 9664752
Lancet Infect Dis. 2005 Nov;5(11):718-25
pubmed: 16253889
Headache. 2005 Jul-Aug;45(7):926-31
pubmed: 15985111
Headache. 2006 Feb;46(2):200-7
pubmed: 16492228
Neurol Sci. 2015 Feb;36(2):203-8
pubmed: 25190547
Ann Neurol. 2020 Jun;87(6):939-949
pubmed: 32239542
Int J Neurosci. 2020 Apr;130(4):330-335
pubmed: 31623501
Med Hypotheses. 1992 Oct;39(2):168-74
pubmed: 1461182
Physiol Rev. 2017 Apr;97(2):553-622
pubmed: 28179394
Cephalalgia. 2023 Feb;43(2):3331024221146314
pubmed: 36759317
Headache. 2021 Mar;61(3):536-545
pubmed: 33724462
Pharmaceuticals (Basel). 2010 Jun 17;3(6):1966-1987
pubmed: 27713337
Adv Sci (Weinh). 2021 Aug;8(15):e2004433
pubmed: 34114369
Clin J Pain. 2010 Oct;26(8):690-3
pubmed: 20664340
Cephalalgia. 2015 Aug;35(9):801-6
pubmed: 25416323
Int Anesthesiol Clin. 2007 Spring;45(2):27-37
pubmed: 17426506
Science. 2013 Mar 1;339(6123):1092-5
pubmed: 23449592
J Neuroimmunol. 2017 Dec 15;313:138-144
pubmed: 28950996
Headache. 2005 Oct;45(9):1224-8
pubmed: 16178953
Neurol Neurochir Pol. 2013 Jul-Aug;47(4):357-62
pubmed: 23986426
Headache. 2003 Jan;43(1):63-8
pubmed: 12864761
Headache. 1987 Mar;27(3):138-42
pubmed: 3036747
Eur Rev Med Pharmacol Sci. 2011 Oct;15(10):1111-6
pubmed: 22165670
Pain Res Manag. 2013 Nov-Dec;18(6):301-6
pubmed: 23957020
Cephalalgia. 2004;24 Suppl 1:9-160
pubmed: 14979299
Semin Immunopathol. 2018 May;40(3):301-314
pubmed: 29568973
Pharmacol Rep. 2010 Mar-Apr;62(2):287-91
pubmed: 20508283
J Headache Pain. 2016;17:59
pubmed: 27245683
Cephalalgia. 2003 Feb;23(1):55-8
pubmed: 12534582
Clin Exp Immunol. 2022 Jan 28;207(1):11-26
pubmed: 35020858
Int J Neurosci. 1991 Nov;61(1-2):53-60
pubmed: 1667186
Curr Pain Headache Rep. 2005 Dec;9(6):415-22
pubmed: 16282042
Neurol Sci. 2015 Apr;36(4):535-40
pubmed: 25417066
Headache. 1996 May;36(5):312-5
pubmed: 8682673
J Pain Res. 2020 Mar 11;13:537-545
pubmed: 32210609